{"url_path":"/sec/bicx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1443863/0001477932-26-003159-index.html","accession_number":"0001477932-26-003159","cik":"0001443863","ticker":"BICX","issuer_name":"BioCorRx Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1443863/0001477932-26-003159-index.html","primary_entity_key":"0001443863","primary_entity_name":"BioCorRx Inc."},"word_count":292,"has_tables":true,"body_markdown":"ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS\n\n \n\nThe shares of common stock listed below were issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, afforded by Section 4(a)(2) thereof for the sale of securities not involving a public offering:\n\n \n\nDuring the three months ended March 31, 2026, the Company issued an aggregate of 289,171 shares of its common stock for services rendered valued at $108,375 based on the underlying market value of the common stock at the date of grant among which 75,000 shares valued at $30,000 were issued to the board of directors for board compensation.\n\n \n\n \n\n46\n\n*Table of Contents*\n\n \n\nDuring the three months ended March 31, 2026, the Company issued 1,470,588 shares of its common stock in connection with the 2026 Q1 Subscription Agreement. The shares were issued at a purchase price of $0.34 per share for a total purchase price of $500,000.\n\n \n\nDuring the three months ended March 31, 2026, the Company issued 294,118 shares of its common stock at $0.34 per share in connection with conversion of the related party promissory note then outstanding of $100,000. As the fair value of the shares issued equaled the carrying amount of the note, no gain or loss was recognized.\n\n \n\nDuring the three months ended March 31, 2026, the Company issued 2,263,371 shares of its common stock in connection with the acquisition of 12.15% ownership interest in its subsidiary.\n\n \n\nDuring the three months ended March 31, 2026, the Company issued an aggregate of 100,000 shares as consideration to the holders of promissory notes entering into the amended agreements to the promissory notes (see Note 10). The 100,000 shares of common stock were valued at an aggregate value of $40,000."}